Syndax Pharmaceuticals Releases Positive Outcomes for Revuforj from Recent Trials in AML Research Syndax Pharmaceuticals reveals encouraging data for Revuforj® in treating relapsed or refractory acute myeloid leukemia, marking a significant milestone in cancer therapy.

Syndax Pharmaceuticals Releases Positive Outcomes for Revuforj from Recent Trials in AML Research #USA #Waltham #Syndax_Pharmaceuticals #Revuforj #AML_Trials